Aflac Incorporated reported significant financial performance improvements in its latest 10-Q filing for the third quarter of 2025, with total revenues reaching $4.74 billion, a substantial increase from $2.95 billion in the same period last year. The company's net earnings for the quarter were $1.64 billion, or $3.09 per diluted share, compared to a net loss of $93 million, or $(0.17) per diluted share, in the third quarter of 2024. For the first nine months of 2025, total revenues were $12.30 billion, down from $13.52 billion in the prior year, while net earnings were $2.27 billion, or $4.22 per diluted share, compared to $3.54 billion, or $6.26 per diluted share, in the same period of 2024.
The filing highlighted several strategic developments, including a robust share repurchase program, where Aflac repurchased 25.7 million shares for $2.7 billion during the first nine months of 2025. The company also authorized an additional 100 million shares for repurchase in August 2025. Aflac Japan's new cancer insurance product, Miraito, launched in March 2025, contributed to increased sales, with new annualized premium sales rising by 13.5% in the third quarter compared to the previous year. The company reported over 22 million individual policies in force in Japan, with approximately 14 million cancer policies.
Operationally, Aflac's total benefits and claims for the third quarter were $1.44 billion, down from $1.60 billion in the same quarter of 2024, primarily due to reserve remeasurement gains. The company’s total adjusted expenses for the quarter were $1.31 billion, slightly up from $1.26 billion year-over-year. Aflac Japan's net earned premiums decreased by 1.8% to $2.34 billion, while Aflac U.S. saw a 2.5% increase in net earned premiums to $1.50 billion. The company’s total assets increased to $122.31 billion as of September 30, 2025, compared to $117.57 billion at the end of 2024.
The filing also noted that Aflac's shareholders' equity rose to $28.69 billion, or $54.57 per share, from $26.10 billion, or $47.45 per share, at the end of 2024. This increase was attributed to a cumulative effect of changes in discount rate assumptions on insurance reserves, which added $6.83 billion to equity. The company continues to maintain a strong capital position, with a focus on managing liquidity and capital resources effectively. Aflac's outlook remains cautious, with ongoing monitoring of market conditions, particularly regarding foreign currency fluctuations and interest rate risks, which could impact future performance.
About AFLAC INC
Aflac Incorporated is a leading provider of supplemental health and life insurance, primarily serving customers in Japan and the U.S. Its key offerings include cancer and medical insurance products designed to alleviate financial stress during health crises. With a focus on innovation and digital sales, Aflac targets a growing market of consumers facing rising out-of-pocket medical costs. The company is enhancing its product portfolio and expanding distribution channels to meet evolving customer needs.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.